research reports and media, page-707

Here is another way to calculate possible value. I do note. You could run 100’s scenarios
addressable market USA and Australia
30m plus 3m
say market penetration 5%. Now that is conservative!
= 1,650,000 clients
gross rev 1.650m x $1,500 = $2,475,000,000
say after paying a big pharmaceutical company we take home 30% = $742,500,000

now stay with me
$742,500,000/the shares on issue 230,000,000
that = PE $3.22
that times by say 20 (conservative for bio tech)
that equates to a value per share of $64.40

thats pretty crude and very conservative, but with a successful trial 3 in the USA and a TGA approval in Australia- the sky is the limit.

totally amazing, I know

glta

market penetration likely to be greater
cost of medication could easily be more than $1500
deal with big pharmaceutical could be far more lucrative
further global expansion

not to mention other treatments like mps etc.

my god...... I can’t air for trial 3 results.